Correcting eGFR for the effects of ART on tubular creatinine secretion: does one size fit all?

TY - JOUR

T1 - Correcting eGFR for the effects of ART on tubular creatinine secretion

T2 - does one size fit all?

AU - Post, Frank A.

AU - Hamzah, Lisa

N1 - Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine

PY - 2020

Y1 - 2020

N2 - Several antiretrovirals including dolutegravir, rilpivirine and cobicistat inhibit tubular creatinine secretion, leading to benign increases in serum creatinine and reductions in estimated glomerular filtration rate (eGFR). This commentary discusses the magnitude and pattern of eGFR decline, whether this can be overcome by applying a standardized correction factor (as reported by Brunet et al. in Antiviral Therapy), the value of serial eGFR measures to detect rapid eGFR decline and the potential utility of cystatin C as an alternative biomarker of kidney function.

AB - Several antiretrovirals including dolutegravir, rilpivirine and cobicistat inhibit tubular creatinine secretion, leading to benign increases in serum creatinine and reductions in estimated glomerular filtration rate (eGFR). This commentary discusses the magnitude and pattern of eGFR decline, whether this can be overcome by applying a standardized correction factor (as reported by Brunet et al. in Antiviral Therapy), the value of serial eGFR measures to detect rapid eGFR decline and the potential utility of cystatin C as an alternative biomarker of kidney function.

UR - http://www.scopus.com/inward/record.url?scp=85105835647&partnerID=8YFLogxK

U2 - 10.3851/IMP3378

DO - 10.3851/IMP3378

M3 - Article

C2 - 33459634

AN - SCOPUS:85105835647

SN - 2040-2058

VL - 25

SP - 241

EP - 243

JO - Antiviral therapy

JF - Antiviral therapy

IS - 5

ER -